News und Analysen
EQS-Adhoc: Verbio SE: Suspension of dividend for the financial year 2024/25
EQS-Adhoc: Verbio SE: Suspension of dividend for the financial year 2024/25
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of
EQS-Adhoc: Porsche Automobil Holding SE: Adjustment of the forecast for the adjusted group result after tax 2025
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
EQS-News: Scout24 acquires Spanish online real estate platforms Fotocasa and Habitaclia
EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
EQS-News: flatexDEGIRO launches crypto trading in Austria, France, the Netherlands and Spain
EQS-News: HelloFresh SE Announces Intention of Co-Founder and CEO International, Thomas Griesel, to Depart
EQS-Adhoc: HelloFresh SE: Thomas Griesel, co-founder and CEO International of HelloFresh SE, does not intend to extend his Management Board mandate beyond 30 April 2026
EQS-News: Energiekontor AG: Financial close achieved for two further wind park projects in the district of Verden – start of construction ahead
EQS-News: PVA TePla hosts successful Capital Markets Day 2025 and provides strategic outlook
EQS-Adhoc: flatexDEGIRO AG: Management Board aims to merge flatexDEGIRO AG with flatexDEGIRO Bank AG in 2026
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
EQS-News: Sto SE & Co. KGaA: Consolidated turnover declines by 2.3 % to EUR 777.1 million in the first half of 2025
EQS-News: Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter
EQS-News: Energiekontor AG: Energiekontor issues new sustainable corporate bond for renewable energy projects
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic